Vivid Seats shows poor capital efficiency with a Return on Invested Capital (ROIC) of -17.15%, well below its Weighted Average Cost of Capital (WACC) of 5.02%, indicating it is losing value on investments. This contrasts with Sovos Brands, which has a positive ROIC above its WACC, signaling value creation. Other peers like Bowlero, Stagwell, and CareMax also struggle with inefficient capital use, with CareMax showing severe value destruction. This highlights challenges for Vivid Seats and similar companies in generating returns that exceed their funding costs.
Stocks fell sharply due to various factors including a 58.71% drop in the Defiance Daily Target 2x Short PLTR ETF, driven by strong gains in Palantir Technologies, which the ETF inversely tracks. AdaptHealth shares dropped 38.09% amid a legal investi...
Pomerantz LLP is investigating Karyopharm Therapeutics for potential securities fraud related to a retention program granting top executives lump sum cash bonuses between $625,000 and $1,725,000. The announcement led to a 21.45% drop in Karyopharm's ...
LiveOne announced it will release its first quarter fiscal 2027 financial results on August 12, 2026, with a conference call to discuss the performance. The company expects continued year-over-year growth in revenue and adjusted EBITDA, driven by org...
Immix Biopharma appointed Richard Graydon as Chief Medical Officer in March 2026, but he was terminated in July after it was revealed he was actually Ronald L. Fischer, a fugitive wanted since 2005 for rape charges. This revelation led to a 14.15% dr...
Robert W. Baird lowered its price target for Fidelity National Information Services (FIS) from $54.00 to $48.00 following the company's mixed Q2 2026 earnings report. FIS posted strong adjusted EPS of $1.48, beating estimates and showing 8.8% growth ...
